Boryung singed an MOU on cooperation in aerospace medicine with Intuitive Machines of the United States and the German Aerospace Center (DLR) International Astronautical Congress (IAC) on the sidelines of the 75th International Astronautical Congress (IAC), which took place in Milan from Oct. 14 to Oct. 18, the group said.
In February, Intuitive Machines became the first U.S. civilian company to send a lander to the surface of the moon.
The company is to launch a second lunar lander by this year-end. Under the deal, Boryung will organize and support a project related to aerospace medicine along with Intuitive Machines.
Boryung is considering recruiting for the project through the “Humans In Space (HIS) Challenge,” being implemented by the group, it said.
Boryung is also participating in Intuitive Machines’ production of the Moon RACER lunar terrain vehicle (LTV), commissioned by NASA under the Artemis Program.
Boryung said the group was discussing ways of developing a platform for conducting aerospace medicine experiments in the LTV.
Boryung and DLR agreed to utilize “HIS Challenging Accelerating Program” for aerospace medicine research and technology verification expertise and promoting joint research in the years to come.
Beyond that, Boryung said the group also struck an MOU with Thales Alenia Space, a European aerospace company.
Boryung Chairman & CEO Jay Kim said, “Intuitive Machines is a front-runner lunar explorer company with technologies related to NASA’s Artemis Program, and with the latest agreement, Boryung will contribute to expanding Korea’s lunar exploring activities beyond its HIS sector.”
Boryung Likely to Join Club of 1 Trillion Won in Sales
Boryung is forecast to achieve a good performance on the back of the growth of the new hypertension drug “Kanarb”, in the anti-cancer drug segment, in the fourth quarter of this year.
The group is poised to achieve a feat of posting 1 trillion won in sales this year, a financial information institution said.
Sales consensus for the fourth quarter of this year, released by FnGuide on Dec. 3, showed that Boryung would log 281.3 billion won in sales, a 21.6 percent year-on-year jump, over the same period of last year.
The group’s operating profit consensus was set at 16.8 billion won, a 13.5 percent surge.
If Boryung achieves Q4sales consensus, the group will join the club of posting 1 trillion won in sales in 2024.
During the January-September period of the year, Boryung logged 760.2 billion won in sales, a 21 percent surge over the same period of last year.
If the feat is realized, Boryung will become the eighth pharmaceutical company in Korea to join the club of posting 1 trillion won in sales per year, following Yoohan Corp., Green Cross, Chong Kun Dang, Hami Pharmaceutical, Daewoong Pharmaceutical and Kwang Dong Pharmaceutical.
The leader for Boryung is the new hypertension drug “Kanarb.”
Kanarb, an ARB antihypertensive drug, was developed by Boryung on its own and allowed to be put on the market in 2010.
Kanarb sales are climbing fast, as the drug has continued to expand its line-ups.
The Kanarb family saw yearly sales top 100 billion won in 2021 and surpass 150 billion won last year.
The Kanarb family logged 113.7 billion won in the first nine months of the year, a 10.7 percent year-on-year surge.
_보령 독일 항공우주센터.jpg)
_보령도표_대지 1.jpg)
